Jaguar posts positive trial results on lead prescription drug for dogs

Jaguar Animal Health announced Thursday that during a pilot study of its treatment Canalevia to treat diarrhea, 91% of dogs who received the drug responded positively to it, vs. 50% of dogs who were given a placebo. Canalevia, derived from a compound in Croton lechleri trees, is Jaguar's lead prescription drug candidate and a canine-specific version of Fulyzaq (crofelemer), which was approved by the FDA in 2012 for HIV patients. Fulyzaq is made by Napo Pharmaceuticals--Jaguar's majority shareholder. Jaguar plans to use the Canalevia study results to design a pivotal trial in dogs, which the company expects to complete this year. Release

Suggested Articles

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

VetStem Biopharma has treated more than 12,000 companion animals with stem cells removed from their own bodies and then reinjected to treat a variety of joint…

Miami-based biotech Opko Health is branching out into animal health, joining one of the fastest growing segments of the industry: oncology. But the company--…